**Background**
Muscarinic cholinergic receptors (mAChRs) are G protein-coupled receptors that play a critical role in regulating various physiological processes across the central and peripheral nervous systems. Among these, the M1 receptor subtype is highly expressed in the cerebral cortex and hippocampus, where it modulates cognitive functions, memory, and motor control. Dysregulation of the cholinergic system is a hallmark of several neurological conditions, including Parkinson’s disease and various behavioral or mental disorders. In Parkinson’s disease, an imbalance between dopamine and acetylcholine levels often leads to motor complications such as tremors and rigidity. Consequently, the development of selective muscarinic antagonists is essential for restoring neurotransmitter balance and alleviating symptoms. In this context, we will introduce a muscarinic cholinergic receptor M1 antagonist – Cycrimine.
**Definition**
Cycrimine is an orally active muscarinic cholinergic receptor (mAChR) M1 antagonist. According to the Cycrimine description, this compound is utilized to reduce acetylcholine levels in Parkinson’s disease models and exhibits significant antispasmodic activity.
**Biological Activity**
The Cycrimine biological activity is characterized by its ability to block M1 receptors, thereby inhibiting the effects of acetylcholine. From a chemical perspective, the Cycrimine Formula is $\text{C}_{19}\text{H}_{29}\text{NO}$ with a molecular weight of 287.44. Research indicates that Cycrimine can be effectively applied in studies focusing on behavioral and mental disorders. In terms of pharmacological application, Cycrimine in vivo studies have demonstrated its efficacy as an antispasmodic compound in the treatment of paralysis agitans (Parkinson’s disease), where it helps manage motor dysfunction by modulating cholinergic transmission. Furthermore, the compound has been used in bioisosterism studies to characterize achiral and chiral enantiopure derivatives to better understand its pharmacological profile. In conclusion, Cycrimine is a potent M1 antagonist that serves as a valuable tool for researching cholinergic dysfunction in neurological and psychiatric disorders.
Keywords
Cycrimine, 77-39-4, mAChR, Muscarinic acetylcholine receptor, Parkinson, Ach, mental disorder, behavioral disorder, muscarinic, anticholinergic, PD, Inhibitor, inhibitor, inhibit
References
[1] David T. CHAU. Methods of treating behaviorial and/or mental disorders. WO2014176460A1.
[2] Marzoughi S, et al. Tardive neurotoxicity of anticholinergic drugs: A review. J Neurochem. 2021 Sep;158(6):1334-1344.
[3] Tacke, et al. Syntheses and pharmacological characterization of achiral and chiral enantiopure C/Si/Ge-analogous derivatives of the muscarinic antagonist cycrimine: a study on C/Si/Ge bioisosterism. Journal of organometallic chemistry 640.1-2 (2001): 140-165.
[4] MAGEE KR, et al. Antispasmodic compound 08958 in treatment of paralysis agitans. J Am Med Assoc. 1953 Oct 24;153(8):715-8.